This PDF is the current document as it appeared on Public Inspection on 06/26/2012 at 08:45 am.
The Food and Drug Administration (FDA) is announcing that a collection of information entitled “Experimental Study: Effect of Promotional Offers in Direct-to-Consumer Prescription Drug Print Advertisements on Consumer Product Perceptions” has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT:
Juanmanuel Vilela, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville, MD 20850, 301-796-7651, Juanmanuel.Vilela@fda.hhs.gov.
On October 14, 2011, the Agency submitted a proposed collection of information entitled “Experimental Study: Effect of Promotional Offers in Direct-to-Consumer Prescription Drug Print Advertisements on Consumer Product Perceptions” to OMB for review and clearance under 44 U.S.C. 3507. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0713. The approval expires on June 30, 2015. A copy of the supporting statement for this information collection is available on the Internet at http://www.reginfo.gov/public/do/PRAMain.
Dated: June 18, 2012.
Assistant Commissioner for Policy.
[FR Doc. 2012-15715 Filed 6-26-12; 8:45 am]
BILLING CODE 4160-01-P